Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
This research aims to evaluate how digital parenting education affects mothers knowledge and attitudes about their childrens use of technology and their own social media addiction levels. Conducted as a randomized controlled trial, the study focuses on mothers of healthy preschool children aged 3 to 6 years registered at a family health center. The study seeks to assess the impact of educational sessions on digital parenting awareness and social media habits among these mothers. Participants are randomly assigned to either an experimental group receiving digital parenting education or a control group without intervention during the main study phase. The education consists of eight face-to-face sessions, each lasting 20 minutes, delivered twice a week. The training covers topics such as the role of digital parenting, effects of technology on parent-child relationships and child behavior, appropriate social media use, and managing risks and opportunities of digital tools. The control group completes pre- and post-test assessments and is offered a brief educational session and brochure after the study. Mothers complete questionnaires measuring their knowledge and attitudes about technology use and social media addiction before and after the intervention. Data collection includes sociodemographic information and specific scales on parental knowledge, attitudes, and social media addiction. The study uses statistical methods to compare changes between groups over 12 weeks. Participant involvement includes consent, pre-test, education sessions for the experimental group, post-test, and follow-up assessments. The total study duration spans from March to December 2025.
Actively Recruiting
Breast cancer patients undergoing chemotherapy often face psychological distress, anxiety, and reduced comfort during treatment. This trial evaluates whether mandala coloring during outpatient chemotherapy sessions can help reduce these negative feelings and improve comfort. The study is a randomized controlled experimental trial designed to provide evidence about a simple, low-cost supportive method for enhancing well-being in breast cancer patients receiving chemotherapy. Participants are randomly assigned to either an intervention group or a control group. Those in the intervention group will color mandala patterns for 30 minutes during their chemotherapy session using provided coloring books and pencils, while continuing to receive routine medical care. The control group will receive routine outpatient chemotherapy care without any additional activity. Participants will have their psychological distress, anxiety, and comfort levels measured both before and immediately after the chemotherapy session using validated scales. Researchers will compare these measurements between groups to assess the effect of mandala coloring. The study is expected to provide valuable insights into improving the psychological well-being of breast cancer patients during outpatient chemotherapy sessions.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Imeroprubart in adults with active Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a neurological disorder. This Phase 2b, multi-center, randomized, double-blind, placebo-controlled study focuses on adult participants who meet specific diagnostic criteria for CIDP or its variants. The study is sponsored by Immunovant Sciences GmbH and aims to understand how well Imeroprubart helps prevent relapses and improves disability and muscle strength in this population. Participants will receive either Imeroprubart or a matching placebo by subcutaneous injection once weekly. The initial treatment period lasts 24 weeks, with a further extension period of 52 weeks for continued evaluation. Imeroprubart is given as a dose 1 injection under the skin weekly during these periods, while the placebo group receives matching injections during the first 24 weeks. Throughout the study, participants will be regularly assessed for relapse status, disability scales, grip strength, muscle strength scores, and functional impairment from baseline up to Week 24. These assessments include standardized clinical scales such as the Inflammatory Rasch-Built Overall Disability Scale I-RODS and Medical Research Council Sum Score MRC-SS. Safety and efficacy are closely monitored, with the primary outcome focusing on the proportion of participants remaining relapse-free by Week 24. The total study duration extends until May 2030.
Actively Recruiting
Researchers are evaluating whether adding mandala coloring to routine treatment can improve pain, fatigue, and sleep quality in adults with fibromyalgia, a chronic condition marked by widespread pain, tiredness, and poor sleep. This randomized controlled study will compare these effects between a group doing mandala coloring and a control group receiving only their usual care. Participants will be randomly assigned to either the mandala coloring group or the control group. Those in the coloring group will complete eight 60-minute supervised mandala coloring sessions over four weeks, with two sessions each week, while continuing their usual treatment. The control group will continue their routine treatment without any structured coloring activity during the same period. Participants will undergo assessments at the start and end of the four-week study to measure pain intensity using the Visual Analog Scale, fatigue using the Fatigue Severity Scale, and sleep quality using the Pittsburgh Sleep Quality Index. The study will compare changes in these measures between the two groups to understand the impact of mandala coloring. The trial is sponsored by Artvin Coruh University and is conducted in a clinical outpatient setting.
Actively Recruiting
Researchers are evaluating whether using a stress ball during chemotherapy can help reduce anxiety, fear, and changes in vital signs in patients with gastrointestinal system cancers. This randomized controlled study includes adult patients undergoing chemotherapy, who often experience emotional and physiological stress during treatment. The study aims to provide evidence on whether a simple, non-drug method like stress ball squeezing can improve emotional well-being and physical stability during chemotherapy. Participants will be randomly assigned to one of two groups the stress ball intervention group or the routine care group. Those in the stress ball group will squeeze a medium-firm stress ball for 15 minutes starting at the beginning of their chemotherapy session, guided to inhale while squeezing and exhale while releasing the ball. The control group will receive routine chemotherapy care without additional interventions. Participants will have their anxiety and fear levels measured before and immediately after chemotherapy using validated tools. Vital signs such as blood pressure, heart rate, respiratory rate, body temperature, and oxygen saturation will also be recorded at these times. The study will compare these measures between both groups to assess the impact of stress ball use during chemotherapy. The total duration of participation covers the chemotherapy session with these before-and-after assessments.
Actively Recruiting
Researchers are investigating whether tightly controlling blood pressure during major non-cardiac surgery can reduce serious complications related to poor blood flow, such as heart injury, stroke, kidney damage, infections, sepsis, and death within 30 days after surgery. This international randomized trial compares two approaches to managing blood pressure during surgery to see which might better prevent these serious events. The study involves adults aged 45 and older undergoing major surgeries expected to last at least two hours and requiring general or neuraxial anesthesia. Participants are randomly assigned to one of two groups tight blood pressure management or routine blood pressure management. In the tight management group, medications norepinephrine or phenylephrine are infused to keep the mean arterial pressure MAP at or above 85 mmHg during surgery, and certain blood pressure medications are withheld on the morning of surgery. In the routine management group, blood pressure is managed as usual, with blood pressure medications allowed if the anesthesiologist agrees. Other aspects of anesthesia and postoperative care are handled per standard procedures and clinician judgment in both groups. During the study, participants will be monitored closely through blood pressure measurements and clinical assessments. Researchers will track the occurrence of major perfusion-related complications in the first 30 days after surgery as the primary outcome. They will also assess postoperative delirium during the first four days after surgery. The study includes detailed anesthesia management and hospitalization, aiming to capture important health outcomes while ensuring patient safety. Participation lasts through the initial postoperative period with ongoing monitoring as needed.